Balestrini, S. http://orcid.org/0000-0001-5639-1969
Mei, D. http://orcid.org/0000-0001-6790-6251
Sisodiya, S. M. http://orcid.org/0000-0002-1511-5893
Guerrini, Renzo http://orcid.org/0000-0002-7272-7079
Funding for this research was provided by:
Università degli Studi di Firenze
Article History
Accepted: 29 August 2023
First Online: 27 September 2023
Declarations
:
: Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.
: SB received speaker and consultant honoraria from Angelini, Biocodex and Jazz Pharmaceutics. DM has no competing interests to declare. SMS has received honoraria for educational events from Angelini Pharma, Eisai, Zogenix/UCB and institutional contributions for advisory boards, educational events or consultancy work from Eisai, Jazz Pharma, Stoke Therapeutics, UCB and Zogenix. RG received fees for Advisory Boards from UCB, Zogenix, Biocodex, GW-Jazz Pharmaceutics, Angelini, Takeda and Rapport Therapeutics.
: RG and SB contributed to study conceptualisation, SB and DM performed the literature search, SB drafted the manuscript and RG and SMS critically revised the work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.